193 related articles for article (PubMed ID: 33067866)
1. Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores.
Thomas CD; Mosley SA; Kim S; Lingineni K; El Rouby N; Langaee TY; Gong Y; Wang D; Schmidt SO; Binkley PF; Estores DS; Feng K; Kim H; Kinjo M; Li Z; Fang L; Chapman AB; Cooper-DeHoff RM; Gums JG; Hamadeh IS; Zhao L; Schmidt S; Frye RF; Johnson JA; Cavallari LH
CPT Pharmacometrics Syst Pharmacol; 2020 Dec; 9(12):678-685. PubMed ID: 33067866
[TBL] [Abstract][Full Text] [Related]
2. Effects of paroxetine on the pharmacokinetics and pharmacodynamics of immediate-release and extended-release metoprolol.
Parker RB; Soberman JE
Pharmacotherapy; 2011 Jul; 31(7):630-41. PubMed ID: 21923449
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
4. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.
Kirchheiner J; Heesch C; Bauer S; Meisel C; Seringer A; Goldammer M; Tzvetkov M; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2004 Oct; 76(4):302-12. PubMed ID: 15470329
[TBL] [Abstract][Full Text] [Related]
5. An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy.
Batty JA; Hall AS; White HL; Wikstrand J; de Boer RA; van Veldhuisen DJ; van der Harst P; Waagstein F; Hjalmarson Å; Kjekshus J; Balmforth AJ;
Clin Pharmacol Ther; 2014 Mar; 95(3):321-30. PubMed ID: 24193112
[TBL] [Abstract][Full Text] [Related]
6. Study on genotype and phenotype of novel CYP2D6 variants using pharmacokinetic and pharmacodynamic models with metoprolol as a substrate drug.
Qian J; Xu T; Pan P; Sun W; Hu G; Cai J
Pharmacogenomics J; 2024 Apr; 24(3):13. PubMed ID: 38637522
[TBL] [Abstract][Full Text] [Related]
7. CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction.
Goryachkina K; Burbello A; Boldueva S; Babak S; Bergman U; Bertilsson L
Eur J Clin Pharmacol; 2008 Dec; 64(12):1163-73. PubMed ID: 18648788
[TBL] [Abstract][Full Text] [Related]
8. CYP 2D6*4 polymorphism and interindividual response variation to metoprolol in stage 1 hypertensive patients: no association in a rural Indian population?
Ayyappadihas R; Dhanalekshmi U; Jestin H
Turk J Med Sci; 2015; 45(2):352-7. PubMed ID: 26084127
[TBL] [Abstract][Full Text] [Related]
9. Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol.
Nozawa T; Taguchi M; Tahara K; Hashimoto Y; Igarashi N; Nonomura M; Kato B; Igawa A; Inoue H
J Cardiovasc Pharmacol; 2005 Nov; 46(5):713-20. PubMed ID: 16220080
[TBL] [Abstract][Full Text] [Related]
10. A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics.
Blake CM; Kharasch ED; Schwab M; Nagele P
Clin Pharmacol Ther; 2013 Sep; 94(3):394-9. PubMed ID: 23665868
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects.
Damy T; Pousset F; Caplain H; Hulot JS; Lechat P
Fundam Clin Pharmacol; 2004 Feb; 18(1):113-23. PubMed ID: 14748763
[TBL] [Abstract][Full Text] [Related]
12. Impact of genotype-predicted CYP2D6 metabolism on clinical effects and tolerability of metoprolol in patients after myocardial infarction - a prospective observational study.
Anstensrud AK; Molden E; Haug HJ; Qazi R; Muriq H; Fosshaug LE; Spigset O; Øie E
Eur J Clin Pharmacol; 2020 May; 76(5):673-683. PubMed ID: 31940084
[TBL] [Abstract][Full Text] [Related]
13. Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypes.
Lee CM; Kang P; Cho CK; Park HJ; Lee YJ; Bae JW; Choi CI; Kim HS; Jang CG; Lee SY
Arch Pharm Res; 2022 Jun; 45(6):433-445. PubMed ID: 35763157
[TBL] [Abstract][Full Text] [Related]
14. Influence of the cytochrome P4502D6*4 allele on the pharmacokinetics of controlled-release metoprolol.
Koytchev R; Alken RG; Vlahov V; Kirkov V; Kaneva R; Thyroff-Friesinger U; Rehak E
Eur J Clin Pharmacol; 1998 Aug; 54(6):469-74. PubMed ID: 9776437
[TBL] [Abstract][Full Text] [Related]
15. Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination.
Laurent-Kenesi MA; Funck-Brentano C; Poirier JM; Decolin D; Jaillon P
Br J Clin Pharmacol; 1993 Dec; 36(6):531-8. PubMed ID: 12959269
[TBL] [Abstract][Full Text] [Related]
16. The effect of the CYP2D6 genotype on the maintenance dose of metoprolol in a chronic Dutch patient population.
Poulussen FCP; Peters BJ; Hua KH; Houthuizen P; Grouls RJ; Deenen MJ
Pharmacogenet Genomics; 2019 Sep; 29(7):179-182. PubMed ID: 31107373
[TBL] [Abstract][Full Text] [Related]
17. Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients.
Taguchi M; Nozawa T; Kameyama T; Inoue H; Takesono C; Mizukami A; Hashimoto Y
Eur J Clin Pharmacol; 2003 Sep; 59(5-6):385-8. PubMed ID: 12915955
[TBL] [Abstract][Full Text] [Related]
18. Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate.
Hamadeh IS; Langaee TY; Dwivedi R; Garcia S; Burkley BM; Skaar TC; Chapman AB; Gums JG; Turner ST; Gong Y; Cooper-DeHoff RM; Johnson JA
Clin Pharmacol Ther; 2014 Aug; 96(2):175-81. PubMed ID: 24637943
[TBL] [Abstract][Full Text] [Related]
19. A meta-analysis of the effect of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of metoprolol
.
Li S; Lin H; Sun W; Wang Y; Ding Y; Zhao H; Liu S
Int J Clin Pharmacol Ther; 2017 Jun; 55(6):483-492. PubMed ID: 28139969
[TBL] [Abstract][Full Text] [Related]
20. Effects of polymorphism of the beta(1) adrenoreceptor and CYP2D6 on the therapeutic effects of metoprolol.
Yuan H; Huang Z; Yang G; Lv H; Sang H; Yao Y
J Int Med Res; 2008; 36(6):1354-62. PubMed ID: 19094446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
